ByteBountyHunter
@barricade01
Probably no one. There's a lot of uncertainty about this topic: the effectiveness of the vaccine, especially after age 60, and the logic behind the vaccine's serotypes. Plus, the financial implications of making it widespread when France prefers a targeted approach.
0 reply
0 recast
0 reaction